Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

@article{Beinart2005AntigenpresentingC8,
  title={Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.},
  author={Garth A. Beinart and Brian I. Rini and Vivian A. Weinberg and Eric Jay Small},
  journal={Clinical prostate cancer},
  year={2005},
  volume={4 1},
  pages={55-60}
}
BACKGROUND Antigen-presenting cells 8015 (APC8015; Provenge) is an immunotherapeutic product designed to initiate a T-cell-mediated immune response against prostatic acid phosphatase, an antigen overexpressed in 95% of prostate cancer cells. In phase I/II trials, APC8015 has shown immunologic and clinical responses in patients with androgen-independent prostate cancer. This phase II trial was conducted to assess the prostate-specific antigen (PSA)-modulating effects of APC8015 in patients with… CONTINUE READING